Claire Dupuis1,2,3, Ayman Sabra4, Juliette Patrier1, Gwendoline Chaize5, Amine Saighi4, Céline Féger6, Alexandre Vainchtock5, Jacques Gaillat7, Jean-François Timsit8,9. 1. AP-HP, Medical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018, Paris, France. 2. Université de Paris, INSERM IAME, U1137, Team DesCID, 75018, Paris, France. 3. Medical ICU, Gabriel-Montpied University Hospital, Clermont-Ferrand, France. 4. Pfizer France, Paris, France. 5. HEVA, Lyon, France. 6. EMIBiotech, Paris, France. 7. Infectious Diseases Department, Annecy-Genevois Hospital, Annecy, France. 8. AP-HP, Medical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018, Paris, France. jean-francois.timsit@aphp.fr. 9. Medical ICU, Gabriel-Montpied University Hospital, Clermont-Ferrand, France. jean-francois.timsit@aphp.fr.
Abstract
BACKGROUND: Community-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAP patients admitted in ICUs. METHODS: Data regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models. RESULTS: Among 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006). CONCLUSIONS: P-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs. TRIAL REGISTRATION: N/A (study on existing database).
BACKGROUND: Community-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAPpatients admitted in ICUs. METHODS: Data regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models. RESULTS: Among 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006). CONCLUSIONS:P-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs. TRIAL REGISTRATION: N/A (study on existing database).
Entities:
Keywords:
Community-acquired pneumonia; Comorbidities; Direct costs; Intensive care unit; Long-term outcome; Pneumococcal pneumonia; Streptococcus pneumoniae
Authors: Antoni Torres; Catia Cillóniz; Francesco Blasi; James D Chalmers; Jacques Gaillat; Nathalie Dartois; Heinz-Josef Schmitt; Tobias Welte Journal: Respir Med Date: 2018-02-19 Impact factor: 3.415
Authors: Brandon H Hayes; Dana L Haberling; Jordan L Kennedy; Jay K Varma; Alicia M Fry; Neil M Vora Journal: Chest Date: 2017-10-07 Impact factor: 9.410
Authors: Vicente F Corrales-Medina; Kathryn N Suh; Gregory Rose; Julio A Chirinos; Steve Doucette; D William Cameron; Dean A Fergusson Journal: PLoS Med Date: 2011-06-28 Impact factor: 11.069
Authors: Ryan B Smithee; Tiffanie M Markus; Elizabeth Soda; Carlos G Grijalva; Wei Xing; Nong Shang; Marie R Griffin; Fernanda C Lessa Journal: Health Serv Res Manag Epidemiol Date: 2020-07-24
Authors: Axel de Mangou; Agathe Combe; Nathalie Coolen-Allou; Guillaume Miltgen; Nicolas Traversier; Olivier Belmonte; David Vandroux; Michel Bohrer; Julien Cousty; Margot Caron; Charles Vidal; Jérôme Allyn; Nicolas Allou Journal: PLoS One Date: 2022-04-15 Impact factor: 3.752